Adjuvant Bortezomib Maintenance Therapy After Autologous Peripheral Stem Cell Transplantation in Treating Patients With Intermediate or Advanced Multiple Myeloma

Inclusion Criteria:

* Diagnosis of intermediate or advanced multiple myeloma meeting criteria for at least 1 2 following:
* Intermediate- to high-M-component production rates (immunoglobulin \[Ig\]G \> 5 g/dL or immunoglobulin A (IgA) \> 3 g/dL or urine M component \> 4 g/24 hours)
* More than one osteolytic bone lesion or radiographic evidence of diffuse osteoporosis
* β-2 microglobulin \> 3
* Nonsecretory myeloma if bone marrow plasmacytosis is greater than 30%
* Must have undergone autologous peripheral blood stem cell transplantation within the past 3-4 months
* Age 18 to 69 years old
* Absolute neutrophil count ≥ 1,000/mm\^3
* Platelet count ≥ 30,000/mm\^3
* serum glutamate oxaloacetate transaminase (SGOT) or serum glutamate pyruvate transaminase (SGPT) ≤ 300 IU
* Bilirubin ≤ 2 mg/dL
* Creatinine ≤ 2.0 mg/dL
* Creatinine clearance ≥ 30 mL/min
* Negative pregnancy test
* Fertile patients must use effective contraception

Exclusion Criteria:

* concurrent major cardiac disease that would preclude study participation
* concurrent major pulmonary disease that would preclude study participation
* pregnant or nursing
* peripheral neuropathy ≥ grade 2
* history of hypersensitivity to bortezomib, boron, or mannitol
* concurrent major gastrointestinal or bladder disease that would preclude study participation
* concurrent major neurologic or psychiatric disease that would preclude study participation
* dementia or significantly altered mental status that would preclude giving informed consent
* prior interferon post-transplantation
* prior thalidomide post-transplantation
* prior chemotherapy post-transplantation
* prior radiotherapy post-transplantation
* prior investigational therapy post-transplantation
* prior bortezomib
* prior therapy for myeloma post-transplantation
* other concurrent anti-myeloma therapy
* other concurrent investigational therapy